Caxton Associates (UK)’s Bristol-Myers Squibb BMY Stock Holding History

Caxton Associates (UK)’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,680	Closed	-$256K	–	782
2025 Q3	$256K	Buy	+5,680	New	+$265K	0.01%	576

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Caxton Associates (UK)'s BMY Position: Q4 2025 in Review

Caxton Associates (UK) sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 5,680 shares — an estimated $256K sold.

Caxton Associates (UK) first reported a position in BMY in Q3 2025 and held it in 1 quarter. The position peaked at $256K in Q3 2025. 2,454 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

Caxton Associates (UK) reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
Caxton Associates (UK) sold 5,680 Bristol-Myers Squibb shares in Q4 2025, an estimated $256K.
Caxton Associates (UK) first reported a position in Bristol-Myers Squibb in Q3 2025 and held it in 1 quarter.
Caxton Associates (UK)'s Bristol-Myers Squibb position peaked at $256K in Q3 2025.
2,454 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Caxton Associates (UK)'s 13F filing for Q4 2025, filed 13 Feb 2026.